otelixizumab (ChAglyCD3) / GSK 
Welcome,         Profile    Billing    Logout  

1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
otelixizumab (ChAglyCD3) / GSK
2006-003579-11: Tolerability and Safety of Multiple Dose Regimens of TRX4 Anti-CD3 Monoclonal Antibody in Type 1 Diabetes Mellitus

 
1/2
15
Europe
TRX4 (Monoclonal anti-CD3 Antibody),
TolerRx, Inc.
Type I Diabetes Mellitus
 
11/07

Download Options